Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/ Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2580-2589

  Guo, Fei ^a   Sigua, Celia ^a   Tao, Jianguo ^a   Bali, Purva ^a   George, Prince ^a   Li, Yunqing ^a   Wittmann, Sylvie ^a   Moscinski, Lynn ^a   Atadja, Peter ^b   Bhalla, Kapil ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Novartis Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROTEIN; CELL RECEPTOR; CINNAMIC ACID DERIVATIVE; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYDROXAMIC ACID; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERINE PROTEINASE OMI; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLAST CELL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 9; CASPASES; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DRUG SYNERGISM; ENZYME INHIBITORS; G1 PHASE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LEUKEMIA, T-CELL; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 11144358387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2629     Document Type: Article

References (57)

1. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
2. Wen J, Nimmanapalli R, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000;96:3900-6.
3. Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002;16:67-73.
4. Ashkenazi A, Pai R, Fong S, et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999;104:155-62.
5. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-33.
6. Bodmer J, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
7. Guo F, Bhalla K. The FLIP variation on the TRAIL DISC: doxorubicin conducts the swan song. Cancer Biol Ther 2002;1:528-9.
8. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (Apo-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
9. Strasser A, O'Connor L, Dixit V. Apoptosis signaling. Annu Rev Biochem 2000;69:217-47.
10. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
11. Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (Lond) 2000;406:855-62.
12. Cilenti L, Lee Y, Hess S, et al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem 2003;278:11489-94.
13. Yang, Q.-H., Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) and facilitates caspase activity in apoptosis. Genes Dev 2003;17:1487-96.
14. Turner BM. Cellular memory and the histone code. Cell 2002;111:285-91.
15. Cress WD, Seto E. Histone deacetylase, transcriptional control and cancer. J Cell Physiol 2000;184:1-16.
16. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
17. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998:391:811-4.
18. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002;9:322-32.
19. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003:4:13-8.
20. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci 2000;97:10014-9.
21. Vrana JA, Decker RH, Johnson CR, et al. Induction of apoptosis in human myelomonocytic leukemia cells (U937) by the hybrid polar compound SAHA proceeds through pathways regulated by Bcl-2/Bcl-xL, p21CIP1, and c-Jun/AP1, but independent of p53. Oncogene 1999;18:7016-25.
22. Nimmanapalli R, Fuino L, Stobaugh C, Richon VM, Bhalla K. Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood 2003;101:3236-9.
23. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of Imatinib Mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35.
24. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62.
25. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci 2001;98:10833-8.
26. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22.
27. Hernandez A, Thomas R, Smith F, et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001;130:265-72.
28. Inoue H, Shiraki K, Ohmori S, Sakai T, Deguchi M, Yamanaka T, Nakano T. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med 2002;9:521-5.
29. Guo F, Nimmanapalli R, Paranawithana S, et al. Ectopic overexpression of second mitochondrial-derived activator of caspases (Smac/DIABLO) or co-treatment with N-terminus of Smac peptide potentiates Epothilone derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 2002;99:3419-26.
30. Bullock G, Ray S, Reed JC, et al. Intracellular metabolism of high dose Ara-C and resulting DNA fragmentation and apoptosis of human AML cells possessing disparate levels of p26Bcl-2 protein. Leukemia 1996;10:1731-40.
31. Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-resistant, Bcr-Abl positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin (17-AAG). Cancer Res 2002;62:5761-9.
32. Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome c and caspase-3 activity during Taxol-induced apoptosis. Leukemia 1998;12:1930-6.
33. Wittmann S, Bali P, Donapaty S, et al. Flavopiridol downregulates antiapoptotic proteins and sensitizes human breast cancer cells to Epothilone B-induced apoptosis. Cancer Res 2003;63:93-9.
34. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-9.
35. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
36. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59:4392-9.
37. Deveraux Q, Leo E, Stennicke H, Welsh K, Salvesen G, Reed J Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18:5242-51.
38. Yang Y, Fang S, Jensen J, Weissman A, Ashwell J Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (Wash DC) 2000;288:874-7.
39. Hengartner M. The biochemistry of apoptosis. Nature (Lond) 2000;407:770-5.
40. Nagane MM, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Su Huang H-J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-53.
41. Nimmanapalli R, Perkins C, Orlando M, O'Bryan E, Nguyen D, Bhalla K. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63.
42. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with Etoposide and TRAIL. Mol Cell Biol 2000;20:205-12.
43. Griffin D, Wittman D, Nimmanapalli R, et al. Molecular determinants of Epothilone B derivative (BMS247550)- and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gyn Oncol 2003;89:37-47.
44. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 2000;6:4119-27.
45. Aron JL, Parthun MR, Marcucci G, et al. Depsipeptide (FR901228) induces histone acetylation and inhibtion of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8.
46. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001;276:37879-86.
47. Bin L, Li X, Xu LG, Shu HB. The short splice form of casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Letter 2002;510:37-40.
48. Olsson A, Diaz T, Aguilar-Santelises M, et al. Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 2001;15:1868-77.
49. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002;277:22320-9.
50. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002;16:33-45.
51. Ng C-P, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/ tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 2002;1:1051-8.
52. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res 2001;61:7339-48.
53. Jenuwein T, Allis CD. Translating the histone code. Science (Wash DC) 2001;293:1074-80.
54. Zou H, Li Y, Liu X, Wang X. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
55. Srinivasula SM, Gupta S, Datta P, et al. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem 2003;34:31469-72.
56. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Brit J Haematol 2000;111:196-203.
57. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.